A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve <i>EGFR</i> -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Ramucirumab plus osimertinib significantly prolonged PFS compared with osimertinib alone in patients with TKI-naïve <i>EGFR</i>-mutant NSCLC. The combination is safe and well tolerated.
Authors
- Rachel E. Sanborn (ORCID: https://orcid.org/0000-0003-0542-6054)
- Jhanelle E. Gray (ORCID: https://orcid.org/0000-0003-1304-7062)
- Xiuning Le (ORCID: https://orcid.org/0000-0002-8554-1185)
- Don L. Gibbons (ORCID: https://orcid.org/0000-0003-2362-3094)
- Simon Heeke (ORCID: https://orcid.org/0000-0002-5916-534X)
- Tawee Tanvetyanon (ORCID: https://orcid.org/0000-0002-1287-1757)
- Joshua K. Sabari (ORCID: https://orcid.org/0000-0002-1556-1543)
- Jyoti D. Patel (ORCID: https://orcid.org/0000-0002-7550-2094)
- Shane Rogosin
- Mary J. Fidler (ORCID: https://orcid.org/0009-0004-9180-8626)
- John Victor Heymach (ORCID: https://orcid.org/0000-0001-9068-8942)
- Janet Tu (ORCID: https://orcid.org/0000-0002-1899-3501)
- Andreas Saltos (ORCID: https://orcid.org/0000-0003-3622-026X)
- Yanis Boumber (ORCID: https://orcid.org/0000-0001-5003-248X)
- George Blumenschein
- Carl M. Gay (ORCID: https://orcid.org/0000-0002-4907-0718)
- Christina S. Baik (ORCID: https://orcid.org/0009-0007-0822-9060)
- Ben Creelan (ORCID: https://orcid.org/0000-0002-2728-8070)
- Nisha Mohindra (ORCID: https://orcid.org/0000-0001-5913-1716)
- Benjamin Herzberg
- Yasir Y. Elamin (ORCID: https://orcid.org/0000-0002-5312-909X)
- Richard D. Hall (ORCID: https://orcid.org/0000-0001-5812-8857)
- Elaine Shum (ORCID: https://orcid.org/0000-0002-0390-5716)
- Catherine A. Shu (ORCID: https://orcid.org/0000-0003-0765-7665)
- Young Kwang Chae (ORCID: https://orcid.org/0000-0003-1557-7235)
- Bruna Pellini (ORCID: https://orcid.org/0000-0003-0898-0202)
- Mike Hernández (ORCID: https://orcid.org/0000-0002-5074-5460)
- Rafael Santana-Dávila (ORCID: https://orcid.org/0000-0001-5051-1755)
- Jianjun Zhang (ORCID: https://orcid.org/0000-0001-7872-3477)
- Chul Kim (ORCID: https://orcid.org/0000-0003-0191-8684)
Institutions
- Northwestern University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Georgetown University (US)
- University of Washington (US)
- Columbia University Irving Medical Center (US)
- Providence Portland Medical Center (US)
- Moffitt Cancer Center (US)
- Rush University (US)
- University of Virginia (US)
- New York University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1200/jco.24.00533
- Citations
- 35
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 14.66
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Spectrum Pharmaceuticals
- Karyopharm Therapeutics
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Jazz Pharmaceuticals
- Novocure
- Jounce Therapeutics
- Mersana Therapeutics
- Mirati Therapeutics
- NGM Biopharmaceuticals
- MacroGenics
- G1 Therapeutics
- Eisai
- Genentech
- EMD Serono
- Daiichi Sankyo Europe